CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ: BLUE) today announced key management and board appointments in advance of the company’s planned separation, targeted for mid-October, ...
Hosted on MSN
Valion Bio outlines end-2026 Entolimod GMP validation target as NIAID funds GI-ARS BLA-enabling work
Valion Bio management framed Q1 2026 as the first period following its identity change to VBIO and emphasized federally funded progress for Entolimod under the FDA Animal Rule pathway, saying NIAID ...
Good afternoon. Thank you for attending today's Bio-Rad Second Quarter 2022 Earnings Results Conference Call. My name is Hannah and I will be your moderator for today's call. All lines will be muted ...
The large volumes of bio-waste pose significant health and sanitation hazards. Effective bio-waste management involves value addition and conversion processes to enable the utilization of municipal ...
LOS ANGELES, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio” or the “Company”), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)™ targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results